Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 262Neoplasms 242Prostatic Neoplasms 204Colorectal Neoplasms 187Lung Neoplasms 145Multiple Myeloma 141Neoplasm Metastasis 126Ovarian Neoplasms 123Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 109Melanoma 96Squamous Cell Carcinoma of Head and Neck 93Recurrence 80Endometrial Neoplasms 78Carcinoma, Renal Cell 76Lymphoma, Non-Hodgkin 74Lymphoma 70Stomach Neoplasms 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Carcinoma, Hepatocellular 67Glioblastoma 66Brain Neoplasms 64Sarcoma 62Glioma 62Uterine Cervical Neoplasms 59Head and Neck Neoplasms 59Triple Negative Breast Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 54Urinary Bladder Neoplasms 51

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Digestive System Neuroendocrine Tumor G1 × 30 days × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡